FDA Slams Zydus For Flawed Investigation, 'Unofficial' Books
This article was originally published in Scrip
Executive Summary
The FDA's warning letter against Zydus Cadila's Indian sites has some sharp references to the firm's flawed investigations into warfarin tablet failures, controls over computerized systems and poor documentation practices.